2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1428 Context-dependent roles of TP53 mutations in NPM1c-driven leukemogenesis and therapeutic sensitivity

Tyler Biermann, MS, Jake Liu, MD2, Sucheta Rajaraman3, Madina Sukhanova4, Yasmin Abaza, MD5, Jessica Kaplan Altman, MD6, Grant Challen, PhD7, Weiguo Cui, PhD8, Peng Ji, MD, PhD9, Lucy Godley, MD, PhD10, Christine R Zhang, PhD11
1 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
2 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
3 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
4 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
5 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
6 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
7 Washington University in St Louis, St. Louis, Missouri, United States
8 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
9 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
10 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
11 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Abstract

Nucleophosmin 1 (NPM1) and TP53 are among the most frequently mutated genes in acute myeloid leukemia (AML), yet their mutations rarely coexist. Analysis of multiple AML cohorts revealed strong exclusivity between NPM1 and TP53 mutations in de novo and relapsed AML, whereas rare co-mutated cases were more frequently identified in secondary AML. NPM1c+ AML cells retained the capacity to mount robust p53, p21, and apoptotic responses following irradiation-induced DNA damage, indicating that NPM1c does not functionally abrogate p53 signaling and that functional epistasis alone is insufficient to explain the observed exclusivity. Given that AML-associated TP53 mutations can already be detected during clonal hematopoiesis, a premalignant state prior to AML, we hypothesized that an antecedent TP53 mutation may not establish a molecular and cellular state permissive for efficient NPM1c-driven leukemogenesis.

To determine whether prior mutational context influences Npm1c-mediated leukemogenesis, we introduced inducible Npm1c into hematopoietic cells harboring heterozygous Trp53-R172H, the murine equivalent of human TP53-R175H, and compared them with Dnmt3a-R878H/Npm1c (R8N) cells, in which a permissive CH mutation cooperates with Npm1c. Unlike Dnmt3a-R878H, pre-existing Trp53-R172H did not substantially accelerate Npm1c-driven disease. Instead, Trp53-R172H/Npm1c double-mutant (DH) cells exhibited attenuated myeloid skewing, reduced granulocyte and macrophage progenitor (GMP) expansion, and impaired serial colony formation. These defects occurred despite comparable induction of Hoxa9 and Hoxa10 among Npm1c+ genotypes, demonstrating that HOX activation alone was insufficient to sustain preleukemic progenitor expansion. To capture the early transcriptomic changes induced by Npm1c induction, single-cell RNA sequencing analysis was performed 17 days after the induction. Our results demonstrated that antecedent mutations differentially shaped Npm1c-associated p53 activation and cellular stress. R8N GMPs showed the weakest p53 pathway activation, reduced apoptosis, and sustained progenitor expansion. In contrast, although heterozygous Trp53-R172H weakened p53 activation, DH progenitors displayed enriched cell-cycle and DNA-replication programs accompanied by unresolved DNA damage and depletion of hematopoietic stem and progenitor populations. Following prolonged proliferative demands, surviving DH GMPs adopted a transcriptionally and metabolically compromised state with reduced self-renewal and diminished leukemic identity. These findings suggest that Trp53-R172H incompletely suppressed Npm1c-associated checkpoints and failed to establish the stress-adaptive state required for efficient progenitor maintenance and leukemogenesis. Interestingly, DH cells, when subjected to chronic proliferative stress imposed by secondary transplantation were transformed to cause murine AML, which remained sensitive to Menin inhibition, indicating continued dependence on Npm1c-associated leukemogenic programming while being consistent with a requirement for additional transforming events. Conversely, TP53 loss after NPM1c transformation moderately reduced sensitivity to doxorubicin and Menin inhibitors by attenuating apoptosis, while preserving Menin inhibitor induced differentiation.

Taken together, our data demonstrate that antecedent mutations differentially regulate NPM1c-associated cellular stress, p53 checkpoint engagement, and progenitor fitness. Our results provide a biological basis for the rarity of TP53/NPM1 co-mutated AML and demonstrate that mutation order shapes both leukemic evolution and treatment response.

Tyler Biermann, MS: No relevant conflicts of interest to declare.